olokizumab

06/02/2023 - "This study aimed to assess the relative efficacy and safety of olokizumab at different dosages in patients with active rheumatoid arthritis (RA). "
06/02/2023 - "Comparison of the efficacy and safety of olokizumab at different dosages in patients with active rheumatoid arthritis: a network meta-analysis of randomized controlled trials."
01/01/2023 - "Olokizumab's Effectiveness and Safety in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials."
01/01/2022 - "Larger and longer trials are required to determine the efficacy and safety of olokizumab in patients with rheumatoid arthritis. "
06/01/2023 - "The efficacy and safety of olokizumab for rheumatoid arthritis: a systematic review, pairwise, and network meta-analysis."

12/01/2022 - "To assess the efficacy and safety of olokizumab (OKZ), a monoclonal antibody against the interleukin-6 (IL-6) cytokine, versus placebo (PBO) in patients with prior inadequate response to tumour necrosis factor inhibitors (TNFi-IRs). "
09/01/2014 - "The aim of this 12-week Phase IIb study was to assess the efficacy and safety of olokizumab (OKZ), a humanised anti-IL6 monoclonal antibody, in patients with rheumatoid arthritis (RA) with moderate-to-severe disease activity who had previously failed tumour necrosis factor (TNF) inhibitor therapy. "
12/01/2022 - "Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study."

01/01/2021 - "Impact of olokizumab on platelets, leukocytes and erythrocytes during mild COVID-19."
12/15/2020 - "The use of olokizumab to treat the new COVID-19 coronavirus disease has demonstrated a positive effect on clinical and laboratory parameters. "
12/15/2020 - "[Experience of olokizumab use in COVID-19 patients]."
01/01/2023 - "Efficacy and safety of clazakizumab, olokizumab, siltuximab and levilimab compared to standard care or placebo for treating COVID-19 The evidence about the effects of clazakizumab, olokizumab, siltuximab, and levilimab comes from only one or two studies for each blocking agent, and is uncertain or very uncertain. "
06/30/2021 - "Monoclonal antibodies against IL-6 or IL-6R, such as tocilizumab, sarilumab, siltuximab and olokizumab may serve as therapeutic options for COVID-19 infection."

01/01/2022 - "Adverse events, most commonly infections, occurred in approximately 70% of the patients who received olokizumab. "
06/30/2021 - "Monoclonal antibodies against IL-6 or IL-6R, such as tocilizumab, sarilumab, siltuximab and olokizumab may serve as therapeutic options for COVID-19 infection."

06/02/2023 - "Es wurde eine Bayes-Netzwerk-Metaanalyse zur Kombination direkter und indirekter Evidenz aus randomisierten kontrollierten Studien (RCT) durchgeführt, um die Wirksamkeit und Sicherheit von Olokizumab in der Dosierung von 64 mg/kg alle 2 Wochen (Q2W) oder alle 4 Wochen (Q4W) als i.v.-Gabe bei Patienten mit aktiver rheumatoider Arthritis (RA) zu untersuchen. "
06/02/2023 - "ZIEL: Ziel der vorliegenden Studie war es, die relative Wirksamkeit und Sicherheit von Olokizumab in verschiedenen Dosierungen bei Patienten mit aktiver rheumatoider Arthritis (RA) zu untersuchen. "
01/06/2023 - "ZIEL: In der vorliegenden Studie wurde die relative Wirksamkeit und Sicherheit von Olokizumab, Tocilizumab und Sarilumab bei Patienten mit rheumatoider Arthritis (RA) verglichen, bei denen eine Unverträglichkeit und unzureichende Therapieantwort auf Methotrexat (MTX) bestand. "